New cancer drug combo for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed cervical cancer (types: squamous, adenocarcinoma, or adenosquamous).
- Your cancer is locally advanced (stages IIIA to IVA) with or without lymph node spread.
- You have not had any prior surgery (except partial hysterectomy for other reasons), radiation, or chemotherapy for your cervical cancer.
- You have not had immunotherapy before.
- You are 18 or older and able to care for yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
This trial tests whether adding two drugs (pembrolizumab and lenvatinib) to standard chemoradiation and brachytherapy can improve outcomes for people with high-risk locally advanced cervical cancer. It is designed for patients who are fit enough to undergo intensive treatment.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests combining an immunotherapy drug (pembrolizumab) with a special type of radiation (carbon-ion radiotherapy) for a specific type of advanced cervical cancer called adenocarcinoma or adenosquamous carcinoma. It aims to see if this combination is safe and effective for patients who have not had prior radiation or chemotherapy for their cervical cancer.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
Hear when a new Locally Advanced Cervical Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.